Clinical Trial Update: A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and efficacy of pacritinib in relapsed or refractory Waldenström macroglobulinemia; the trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoproliferative Disorder
• Indolent Lymphoma
• Lymphoplasmacytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Pacritinib (pacritinib)

Snippet

Sponsor: Shayna Sarosiek, MD | Conditions: Waldenström Macroglobulinemia, Lymphoplasmacytic Lymphoma | Phase 2 | Status: RECRUITING